|
|
Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia |
Weina Zhang, Ying Lu, Tao Zhen, Xinjie Chen, Ming Zhang, Ping Liu, Xiangqin Weng, Bing Chen, Yueying Wang() |
State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China |
|
|
Abstract Collaboration of c-KIT mutations with AML1–ETO (AE) has been demonstrated to induce t(8; 21) acute myeloid leukemia (AML). Targeted therapies designed to eliminate AE and c-KIT oncoproteins may facilitate effective treatment of t(8; 21) AML. Homoharringtonine (HHT) features activity against tumor cells harboring c-KIT mutations, whereas oridonin can induce t(8; 21) AML cell apoptosis and AE cleavage. Therefore, studies should explore the efficacy of combination therapy with oridonin and HHT in t(8; 21) AML. In this study, we investigated the synergistic effects and mechanism of oridonin combined with HHT in t(8; 21) AML cell line and mouse model. The two drugs synergistically inhibited cell viability and induced significant mitochondrial membrane potential loss and apoptosis. Oridonin and HHT induced significant downregulation of c-KIT and its downstream signaling pathways and promoted AE cleavage. HHT increased intracellular oridonin concentration by modulating the expressions of MRP1 and MDR1, thus enhancing the effects of oridonin. The combination of oridonin and HHT prolonged t(8; 21) leukemia mouse survival. In conclusion, oridonin and HHT exert synergistic effects against t(8; 21) leukemia in vivo and in vitro, thereby indicating that their combination may be an effective therapy for t(8; 21) leukemia.
|
Keywords
AML1–ETO
c-KIT
homoharringtonine
oridonin
t(8
21) AML
synergistic effect
|
Corresponding Author(s):
Yueying Wang
|
Just Accepted Date: 25 July 2018
Online First Date: 13 September 2018
Issue Date: 05 June 2019
|
|
1 |
B Jiao, CF Wu, Y Liang, HM Chen, SM Xiong, B Chen, JY Shi, YY Wang, JH Wang, Y Chen, JM Li, LJ Gu, JY Tang, ZX Shen, BW Gu, WL Zhao, Z Chen, SJ Chen. AML1–ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia 2009; 23(9): 1598–1604
|
2 |
LM Kelly, DG Gilliland. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002; 3(1): 179–198
https://doi.org/10.1146/annurev.genom.3.032802.115046
|
3 |
GB Zhou, H Kang, L Wang, L Gao, P Liu, J Xie, FX Zhang, XQ Weng, ZX Shen, J Chen, LJ Gu, M Yan, DE Zhang, SJ Chen, ZY Wang, Z Chen. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 2007; 109(8): 3441–3450
https://doi.org/10.1182/blood-2006-06-032250
|
4 |
T Zhen, CF Wu, P Liu, HY Wu, GB Zhou, Y Lu, JX Liu, Y Liang, KK Li, YY Wang, YY Xie, MM He, HM Cao, WN Zhang, LM Chen, K Petrie, SJ Chen, Z Chen. Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. Sci Transl Med 2012; 4(127): 127ra38
https://doi.org/10.1126/scitranslmed.3003562
|
5 |
YY Wang, LJ Zhao, CF Wu, P Liu, L Shi, Y Liang, SM Xiong, JQ Mi, Z Chen, R Ren, SJ Chen. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 2011; 108(6): 2450–2455
https://doi.org/10.1073/pnas.1019625108
|
6 |
YY Wang, GB Zhou, T Yin, B Chen, JY Shi, WX Liang, XL Jin, JH You, G Yang, ZX Shen, J Chen, SM Xiong, GQ Chen, F Xu, YW Liu, Z Chen, SJ Chen. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 2005; 102(4): 1104–1109
https://doi.org/10.1073/pnas.0408831102
|
7 |
J Lennartsson, L Ronnstrand. The stem cell factor receptor/c-Kit as a drug target in cancer. Curr Cancer Drug Targets 2006; 6(1): 65–75
https://doi.org/10.2174/156800906775471725
|
8 |
HM Kantarjian, M Talpaz, V Santini, A Murgo, B Cheson, SM O’Brien. Homoharringtonine: history, current research, and future direction. Cancer 2001; 92(6): 1591–1605
https://doi.org/10.1002/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U
|
9 |
F Alvandi, VE Kwitkowski, CW Ko, MD Rothmann, S Ricci, H Saber, D Ghosh, J Brown, E Pfeiler, E Chikhale, J Grillo, J Bullock, R Kane, E Kaminskas, AT Farrell, RUS Pazdur. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist 2014; 19(1): 94–99
https://doi.org/10.1634/theoncologist.2013-0077
|
10 |
J Jin, JX Wang, FF Chen, DP Wu, J Hu, JF Zhou, JD Hu, JM Wang, JY Li, XJ Huang, J Ma, CY Ji, XP Xu, K Yu, HY Ren, YH Zhou, Y Tong, YJ Lou, WM Ni, HY Tong, HF Wang, YC Mi, X Du, BA Chen, Y Shen, Z Chen, SJ Chen. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2013; 14(7): 599–608
https://doi.org/10.1016/S1470-2045(13)70152-9
|
11 |
HH Zhu, H Jiang, Q Jiang, JS Jia, YZ Qin, XJ Huang. Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21). Leuk Res 2016; 44: 40–44
https://doi.org/10.1016/j.leukres.2016.02.012
|
12 |
SS Lam, ES Ho, BL He, WW Wong, CY Cher, NK Ng, CH Man, H Gill, AM Cheung, HW Ip, CC So, J Tamburini, CW So, DN Ho, CH Au, TL Chan, ES Ma, R Liang, YL Kwong, AY Leung. Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia. Sci Transl Med 2016; 8(359): 359ra129
https://doi.org/10.1126/scitranslmed.aaf3735
|
13 |
Y Jin, Z Lu, K Cao, Y Zhu, Q Chen, F Zhu, C Qian, J Pan. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation. Mol Cancer Ther 2010; 9(1): 211–223
https://doi.org/10.1158/1535-7163.MCT-09-0468
|
14 |
TC Chou. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58(3): 621–681
https://doi.org/10.1124/pr.58.3.10
|
15 |
R Tang, AM Faussat, P Majdak, C Marzac, S Dubrulle, Z Marjanovic, O Legrand, JP Marie. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther 2006; 5(3): 723–731
https://doi.org/10.1158/1535-7163.MCT-05-0164
|
16 |
JI Fletcher, M Haber, MJ Henderson, MD Norris. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010; 10(2): 147–156
https://doi.org/10.1038/nrc2789
|
17 |
D Koley, AJ Bard. Inhibition of the MRP1-mediated transport of the menadione-glutathione conjugate (thiodione) in HeLa cells as studied by SECM. Proc Natl Acad Sci USA 2012; 109(29): 11522–11527
https://doi.org/10.1073/pnas.1201555109
|
18 |
XF Hu, A Slater, DM Wall, JD Parkin, P Kantharidis, JR Zalcberg. Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line. Clin Cancer Res 1996; 2(4): 713–720
|
19 |
W Obuchi, S Ohtsuki, Y Uchida, K Ohmine, T Yamori, T Terasaki. Identification of transporters associated with Etoposide sensitivity of stomach cancer cell lines and methotrexate sensitivity of breast cancer cell lines by quantitative targeted absolute proteomics. Mol Pharmacol 2013; 83(2): 490–500
https://doi.org/10.1124/mol.112.081083
|
20 |
M Abbaspour Babaei, B Kamalidehghan, M Saleem, HZ Huri, F Ahmadipour. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des Devel Ther 2016; 10: 2443–2459
https://doi.org/10.2147/DDDT.S89114
|
21 |
K Stankov, S Popovic, M Mikov. C-KIT signaling in cancer treatment. Curr Pharm Des 2014; 20(17): 2849–2880
https://doi.org/10.2174/13816128113199990593
|
22 |
EK Allan, TL Holyoake, AR Craig, HG Jorgensen. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia: official journal of the Leukemia Society of America. Leukemia 2011; 25(6): 985–994
|
23 |
R Chen, L Guo, Y Chen, Y Jiang, WG Wierda, W Plunkett. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 2011; 117(1): 156–164
https://doi.org/10.1182/blood-2010-01-262808
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|